Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Moderately addictive with a high potential for abuse and capable of causing psychological dependence. Compulsive redosing is a common pattern, with users entering an almost automatic state of redosing regardless of whether the effects remain pleasant. The short duration contributes to repeated administration, and once use deviates from planned limits, escalation is common.
When addiction has developed, cravings and withdrawal effects may occur upon cessation. Physical dependence appears less prominent than psychological dependence, with sources primarily emphasizing compulsive use patterns rather than severe physical withdrawal.
The exact toxic dosage is unknown. NEP has an extremely brief history of human usage and its toxicity has not been studied in any scientific context.
Increases heart rate significantly compared to other stimulants, even at low doses, along with elevated blood pressure and occasional abnormal heartbeat; acute myocardial infarction, arrhythmias, and stroke are presumed possible with large overdoses, though no formal data exists.
Intranasal use causes nasal discomfort and irritation; heavy use can produce significant nasal inflammation and occasionally bleeding, though severity varies substantially between batches.
Extended use at high dosages can result in stimulant psychosis presenting with paranoia, hallucinations, and delusions. Compared to classic stimulants, paranoia, visual distortions, and unusual thinking appear to have faster onset, potentially becoming apparent within one day of heavy use. Sleep deprivation significantly increases risk. The most concerning effects can almost always be prevented by avoiding sleep deprivation and limiting use duration.
No case reports of NEP-induced seizures exist, but like other stimulants it likely has seizure-inducing capacity. Best avoided in those with preexisting seizure disorders.
N-Ethylpentedrone emerged on the online research chemical market during the mid-2010s, with documented user experience reports beginning to appear around 2016. The compound represents a generation of synthetic cathinone derivatives developed as functional and structural alternatives to earlier…
Prohibited substance under a cathinone blanket ban provision. As a Schedule 9 substance, no therapeutic use is recognized and possession, production, and distribution are illegal.
While not individually listed, NEP may be treated as a Schedule I substance under the Controlled Drugs and Substances Act due to provisions banning derivatives of amphetamine.
Classified as a narcotic substance (stupéfiant) as a derivative of cathinone with alkyl substitutions on the nitrogen and R2 position. Possession, purchase, sale, and manufacture are illegal.
Added to Table 1 of psychotropic substances on December 29, 2020. As a Table 1 substance, it is subject to the strictest controls under Italian drug legislation.
Currently unscheduled and legal to possess. However, it belongs to a substance group that may become prohibited under recently enacted New Psychoactive Substances (NPS) legislation.
Regulated as a defined derivative of cathinone under Verzeichnis E point 1 of the narcotics legislation. An exception exists for scientific or industrial purposes, which remain legal with appropriate authorization.
Not federally scheduled under the Controlled Substances Act. However, possession or distribution intended for human consumption could potentially be prosecuted under the Federal Analogue Act due to structural and pharmacological similarities to pentedrone, which is a Schedule I controlled substance.
All cathinone analogues became controlled substances on September 7, 2018, through a blanket ban appended to Portaria SVS/MS nº 344. Possession, use, and distribution are illegal.
Listed as a controlled substance under national drug legislation. Production, distribution, and possession without authorization are prohibited.
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016. Production and importation for market distribution, administration to others, and trading are punishable offenses. Possession is illegal but not subject to criminal penalties.
Designated as a controlled substance under national drug control legislation. Possession, distribution, and manufacturing are prohibited.
Classified as a controlled substance since November 12, 2019. Subject to Swedish narcotics legislation with penalties for possession, distribution, and manufacturing.
Controlled as a Class B substance under the Misuse of Drugs Act 1971 through a cathinone catch-all clause. Possession carries penalties of up to five years imprisonment, while supply offenses carry up to fourteen years.
27 sources cited